GlassScriptPhysician profile
Devraj J Chavda
NPI 1558814889
$7,369.01
in general payments reported to CMS, 2019-2025
35 companies · $2,997 in 2025
The $2,997 reported for 2025 was more than what 82% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $365 · 2023: $1,842 · 2024: $2,165 · 2025: $2,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,131 · Travel and Lodging: $872 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.61 |
| Travel and Lodging | $872.21 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,813.86 | 2023-2025 | |
| Ucb, INC. | $1,189.15 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Ns Pharma, INC. | $440.24 | 2023-2025 | Viltepso |
| Acadia Pharmaceuticals INC | $427.39 | 2023-2025 | Daybue |
| Livanova USA, INC. | $373.82 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Sk Life Science, INC. | $335.91 | 2024-2025 | |
| Sarepta Therapeutics, INC. | $293.75 | 2022-2025 | Elevidys |
| Biogen, INC. | $259.27 | 2023-2025 | Spinraza |
| Catalyst Pharmaceuticals, INC. | $256.68 | 2024-2025 | |
| Neurelis, INC. | $238.74 | 2023-2025 | Valtoco |
| Itf Therapeutics LLC | $228.40 | 2024-2025 | |
| Ptc Therapeutics, INC. | $223.97 | 2022-2024 | Emflaza |
| Genentech USA, INC. | $209.21 | 2023-2025 | Evrysdi |
| Biocodex, INC. | $176.72 | 2023-2025 | Diacomit |
| Immedica Pharma US, INC. | $106.16 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $101.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $80.15 | 2022-2024 | Dysport |
| Ironshore Pharmaceuticals INC. | $78.04 | 2024 | |
| Pyros Pharmaceuticals, INC. | $75.15 | 2024 | Vigpoder |
| Alexion Pharmaceuticals, INC. | $67.19 | 2022-2025 | Koselugo |
| Novartis Pharmaceuticals Corporation | $50.83 | 2025 | |
| Eisai INC. | $47.76 | 2022 | |
| Aquestive Therapeutics, INC. | $44.87 | 2024 | |
| Amneal Pharmaceuticals LLC | $32.07 | 2023 | Lyvispah |
| Intrabio INC | $28.87 | 2025 | Aqneursa |
| Springworks Therapeutics, INC. | $26.49 | 2025 | Gomekli |
| Azurity Pharmaceuticals, INC. | $22.23 | 2025 | Zonisade |
| Pfizer INC. | $21.96 | 2023 | |
| Sunovion Pharmaceuticals INC. | $21.68 | 2022 | |
| Nobelpharma America, LLC | $21.09 | 2025 | |
| Cranial Technologies, INC | $20.65 | 2023 | Doc Band |
| Aucta Pharmaceuticals, INC. | $20.62 | 2024-2025 | Motpoly Xr |
| Biomarin Pharmaceutical INC. | $17.95 | 2024 | Brineura |
| Avadel Cns Pharmaceuticals, LLC | $15.79 | 2025 | Lumryz |
| Travere Therapeutics, INC. | $0.83 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devraj Chavda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.